Central Diabetes Insipidus
A deficiency of antidiuretic hormone from the pituitary gland causing excessive urination (often >3L/day) of dilute urine and intense thirst.
Emergency Management: Adrenal crisis (if panhypopituitarism co-exists) or profound hypernatremic dehydration. Manage with careful IV hypotonic fluids (e.g., D5W or 0.45% NS) to lower serum sodium by no more than 0.5 mEq/L/hour to avoid cerebral edema.
Central Diabetes Insipidus (CDI) is a polyuric condition resulting from a deficiency in the synthesis or release of antidiuretic hormone (ADH, also known as arginine vasopressin) from the posterior pituitary gland. It is characterized by the passage of large volumes of dilute urine (polyuria) and secondary excessive thirst (polydipsia).
Detailed Overview
Without ADH, the renal collecting ducts remain impermeable to water, leading to an inability to concentrate urine. If thirst mechanisms are intact and access to water is unrestricted, patients maintain normal serum osmolality. However, in states of altered mentation, lack of water access, or defective thirst (adipsic CDI), severe hypernatremia and life-threatening dehydration can rapidly develop. Treatment relies on replacing the deficient hormone.
Epidemiology & Demographics
Rare, with a prevalence of about 1 in 25,000. It can occur at any age but is most commonly diagnosed between 10 and 20 years of age, and affects males and females equally. Primary tumors and surgery account for the majority of acquired cases.
Etiological Mechanism
Idiopathic (autoimmune destruction, ~30%), benign or malignant primary/secondary tumors (craniopharyngioma, germinoma, pituitary adenoma), neurosurgery or trauma, infiltrative diseases (sarcoidosis, Langerhans cell histiocytosis), and genetic mutations (AVP-NPII gene).
Primary Causes
Destruction or dysfunction of the magnocellular neurons in the supraoptic and paraventricular nuclei of the hypothalamus, or interruption of the pituitary stalk.
Arginine vasopressin (AVP) is normally synthesized in the hypothalamus and transported via the pituitary stalk to the posterior pituitary for storage and release. In CDI, destruction of more than 80% of these vasopressinergic neurons leads to AVP deficiency. Without AVP binding to V2 receptors in the renal collecting duct, aquaporin-2 water channels are not inserted into the apical membrane, leading to massive free water loss, plasma hyperosmolality, and stimulation of thirst.
Diagnostic Criteria & Guidelines
Confirmed by polyuria (>50 mL/kg/day), dilute urine (urine osmolality < 300 mOsm/kg, usually <100), and normal or high serum sodium/osmolality. Water Deprivation Test demonstrates failure to concentrate urine, with an >50% increase in urine osmolality following exogenous DDAVP administration (differentiates from NDI).
Desmopressin (DDAVP), a synthetic analog of AVP. Dosing is highly individualized. Oral: 0.1 to 0.2 mg once to TID. Intranasal: 10 to 40 mcg daily in 1 to 3 divided doses. Subcutaneous/IV: 1 to 2 mcg BID.
Second-Line & Adjunctive Therapy
For partial CDI: Thiazide diuretics (e.g., Hydrochlorothiazide 25 mg/day) and NSAIDs (e.g., Indomethacin) to induce mild volume depletion and reduce urine output; Chlorpropamide (a sulfonylurea that potentiates AVP action) 125-250 mg/day, though rarely used due to hypoglycemia risk.
Surgical & Procedural Management
Surgical resection of underlying pituitary/hypothalamic mass (e.g., craniopharyngioma) if present, though this often causes or worsens CDI.
Patient Counseling & Advice
Educate the patient on the risk of hyponatremia. The patient should delay one dose of DDAVP until polyuria 'breaks through' (i.e., wait until they feel the need to urinate a large amount before taking the next dose) to prevent fluid overload.
Follow-Up & Monitoring Schedule
Check serum sodium every 3-6 months. Monitor clinical symptoms of polyuria and polydipsia. Periodic MRI if an underlying lesion is being monitored.
Preventive Strategies
Cannot be prevented, but fatal hypernatremia is prevented by reliable water access and correct DDAVP dosing.
Excellent with proper DDAVP replacement therapy. Lifespan is generally normal, assuming any underlying primary condition (like a tumor) is managed.